Cookie Consent
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
With the increasing incidence of respiratory diseases and allergies worldwide, the need for clinical trial expertise in these areas is essential to running a successful clinical study or a full clinical development program. A key quality that distinguishes SCOPE is our ability to provide strong expertise and support to meet enrollment goals on time and within budget. SCOPE can help develop and deliver the enrollment strategy for your respiratory or allergy clinical trial.
In business since 2000, we have conducted over 300 studies with over 88.000 subjects world-wide. We have offices in 11 countries across Europe with over 200 permanent employees. With our partner network, we are operational across all continents and markets wherever clinical trial services are required. SCOPE has significant experience in conducting phase II-IV respiratory clinical trials, ranging from a single protocol to full development programs. In recent years, we have conducted more than 37 studies in the respiratory area for various disease states.
Our patient recruitment, site management and extensive support strategies are uniquely adapted to the specific therapeutic areas and clinical development stages of your product. With our expertise and experience, we can make sure your trial runs as efficiently as possible, meeting all regulatory standards while ensuring consistent quality.
Whether it’s a clinical development trial (phase I-III), post-authorization (phase IV), rescue, adaptive design study, or even a complex device or diagnostic combination design, we have the expertise, know-how, and resources to guide you smoothly through all phases of development while meeting your objectives in a timely and cost-efficient manner.
Our team of clinical project managers, clinical research associates (CRAs), data managers, experienced biostatisticians and medical staff are well-versed in managing and monitoring the procedures associated with objectives and end points used in many respiratory protocols.
We value strong relationships with clinical investigators and key opinion leaders, and our expertise enables us to provide rapid feasibility and consulting services on a wide variety of respiratory protocol concepts and designs. As a result, our pharmaceutical and biotech clients can make decisions quickly and move their development programs forward at a rapid pace.
Our expertise in respiratory development enables us to accomplish recruitment of clinical research projects using the experience of each member of our project team to ensure the successful outcome of your important projects. SCOPE provides a well-established approach for successful respiratory trials.
SCOPE project teams are experts in the design and delivery of site training to ensure protocol-consistent enrollment and efficacy assessments, using electronic data capture systems (EDC, eCOA e.g. ePRO) and innovative study tools including our own project management tool.
Project Team
Device Experience
Our team of Biostatisticians provide advice about study design with reference to randomization & stratification, non-inferiority and adaptive design. Additionally, SCOPE supports post-marketing and pharmacoeconomic assessments.
e.g. Arthritis-related Pain, Bladder Pain Syndrome, Cancer Pain, Chronic Pain, Headache / Migraine, Lower Back Pain, Neuropathic Pain (diabetic, postherpetic), Postoperative Pain Management, Rheumatic Pain, Acute Postoperative / Procedural Pain
e.g. ART (IVF, ICSI), Contraception, Endometriosis, Fibromyalgia Syndrome (FMS), Obstetrics, Oncology, Pain Management, PCOS, Polymyalgia Rheumatica, Postmenopausal Complaints, Preterm labor, Rheumatoid Arthritis, Vulvar and Vaginal Atrophy, Vulvovaginal Candidiasis
e.g. Asthma (mild, moderate, severe, paediatric), Asthma / COPD Overlap Syndrome (ACOS), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired Pneumonia (CAP), COVID-19, Respiratory Virus Infection (including paediatric)
e.g. Alzheimer’s Disease, Bipolar Disorder, Depression, Epilepsy (including paediatric), Mania, Multiple Sclerosis, Narcolepsy, Parkinson’s Disease, Sensorineural Disorder
e.g. Community-acquired pneumonia (CAP), COVID-19, GI and Intra-Abdominal Infections, Immune-Modulator to prevent SARS-CoV Complication, Respiratory Virus Infections (including paediatric)
e.g. Cell and Gene Therapies, Early-Phase Clinical Development of ATMPs, Immunotherapy, Personalized Therapies, Regenerative Medicine
e.g. acute myocardial infarction, hypertension, peripheral arterial disease (PAD), pulmonary arterial hypertension (PAH) and stable angina pectoris
e.g. allergy (allergic conjunctivitis/ rhinoconjunctivitis), dermatomyositis, primary immunodeficiency diseases (PIDs) and vaccination (hepatitis B, influenza, rabies, tuberculosis)
e.g. acute porphyria and type 1 diabetes
e.g. hematological malignancy, liver cancer, metastatic breast cancer, metastatic lung tumor, non-Hodgkin lymphoma, prostatic cancer, renal cancer, schwannoma resection, solid tumors, unresectable cholangiocarcinoma and urinary bladder cancer
e.g. caries prophylaxis
e.g. alopecia areata, hypertrophic scars and psoriasis
e.g. acute porphyria, hormone replacement therapies in women, type 1 diabetes and vitamin D deficiency
e.g. acute porphyria, cholecystectomy, colitis ulcerosa, constipation, fat absorption in HIV-infected patients, inflammatory bowel disease (IBD), intra-abdominal infections, irritable bowel syndrome (IBS), liver disease, cholecystectomy and unresectable cholangiocarcinoma
e.g. hepatitis B vaccination, hepatic impairment, liver cancer and liver disease
e.g. Alzheimer’s, asthma, colitis ulcerosa, osteoarthritis, Parkinson’s Disease, polymyalgia rheumatica (PMR), psoriasis and rheumatoid arthritis
e.g. allergic conjunctivitis, keratoconjunctivitis and retinopathy
e.g. acute porphyria, juvenile dermatomyositis, polymyalgia rheumatica (PMR), pulmonary arterial hypertension (PAH) and sudden sensorineural hearing loss (SSNHL)
e.g. cartilage defects, open Gustilo-Anderson grade IIIa/IIIb tibia shaft fractures and osteoarthritis
e.g. acute peripheral vertigo, acute sensorineural hearing loss (ASNHL), rhinoconjunctivitis and sudden sensorineural hearing loss (SSNHL)
e.g. bladder pain syndrome, prostatic cancer, renal cancer, renal dysfunction / failure
and urinary bladder cancer
e.g. hepatitis B, influenza, rabies and tuberculosis
